Mer­ck KGaA’s evo­bru­ti­nib dis­ap­points in PhI­II mul­ti­ple scle­ro­sis test, cast­ing dark cloud over BTK class

Mer­ck KGaA’s BTK in­hibitor has failed to meet the pri­ma­ry end­point in a pair of reg­is­tra­tional tri­als in re­laps­ing mul­ti­ple scle­ro­sis (RMS), a dis­ap­point­ment that could read through to oth­er Big Phar­ma can­di­dates vy­ing for suc­cess in the same space, ac­cord­ing to an­a­lysts.

The Phase III EVO­LU­TION tri­als stud­ied Mer­ck KGaA’s evo­bru­ti­nib ver­sus stan­dard of care Auba­gio in RMS pa­tients with the pri­ma­ry end­point of re­duc­tion in an­nu­al­ized re­lapse rates (ARR) for up to 156 weeks. Evo­bru­ti­nib did not reach sta­tis­ti­cal sig­nif­i­cance ver­sus Sanofi’s Auba­gio in ei­ther of the stud­ies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER